Actionable news
0
All posts from Actionable news
Actionable news in INCY: Incyte Corporation,

Neuralstem CUR shares plunge on depression data; Tetraphase TTPH positive IGNITE4 data

Price and Volume Movers

Neuralstem, Inc. (Nasdaq:CUR) shares slumped to close down 50% TO $2.81 following its announcement that its Phase 2 trial of NSI-189 for the treatment of major depressive disorder (MDD) did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS).

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced positive top-line results from IGNITE4, its Phase 3 clinical trial evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of patients with complicated intra-abdominal infections (cIAI). The trial met its primary efficacy endpoint and the company plans to file an NDA in 1Q 2018. Shares are trading up 25% to $8.60 in the after-hours session.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) issued a statement that it has not yet received correspondence from the FDA regarding its New Drug Application for RYANODEX for the treatment of exertional heat stroke. The PDUFA date, which is now overdue, was Sunday, July 23, 2017.

Eli Lilly and Company ( NYSE : LLY) and Incyte Corporation (NASDAQ: INCY) announced today that their resubmission of the NDA for baricitinib, for the treatment of moderate-to-severe rheumatoid arthritis (RA), will be delayed for at least 18 months. The companies received a Complete Response Letter (CRL) in April 2017.

Flex Pharma, Inc. (NASDAQ:...


More